About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, November 1st, 2012

The QualityStocks
Daily Stock List


Smoky Market Foods, Inc. (SMKY)

Willy Wizard and Release Hotline reported previously on Smoky Market Foods, Inc. (SMKY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Smoky Market Foods, Inc. uses proprietary, custom-engineered, USDA-approved wood-burning oven technology to produce a complete line of fully cooked Smoke-Baked™ meat and fish, and special recipe dishes. The Company produces their smoked foods from a 15-acre food production campus located in central Iowa. They produce these products for multiple channels of foodservice and retail grocery distribution principally under the Smoky Market brand. Smoky Market Foods lists on the OTCQB; the Company has their headquarters in Webster City, Iowa.

Smoky Market Foods also intends to produce certified kosher smoked foods and to distribute this line of products under the "Smoky Kosher" brand via the same marketing channels. The Company, using their mass production technique, plans to develop a national chain of fast-casual barbecue restaurants under the name "BarBQ Diner". These restaurants would operate without having to handle and cook raw product on site.

Smoky Market Foods operates as a holding company of three business divisions. These were established to generate revenue from branded distribution on a national and international scale.  Smoky Market operates in the retail sector and generates revenue by way of on-line ordering and POS display merchandising of premium quality, wood-smoked prepared foods.

Smoky Kosher will operate in the retail sector and generate revenue through on-line ordering and POS display merchandising of premium quality, wood-smoked foods prepared Kosher and in strict accordance to certification standards of the Orthodox Union for Kosher food. BarBQ Diner will operate in the "fast-casual" foodservice sector. It will generate revenue via innovative franchising of "no-cook" modular restaurants.

Last Friday, Smoky Market Foods released an updated report on the status of their operations since announcing the recruitment of two retail executives in early September. The released report highlighted certain qualifications to their plan for financing. It included other applicable information relative to product distribution and capital structure in anticipation of the Company's forthcoming third quarter 10Q filing.

Upon releasing the updated report, Mr. Eddie Feintech, Chairman, President/CEO of Smoky Market Foods stated that, "the company's management team had been focused on one specific objective since our September news release, which was to position SMKY to receive qualified financing by establishing confirmed channels for distribution and providing such warranties to investors. That objective has been achieved and continues to be enhanced while we pursue financing, and now includes some of the largest grocery chains in the country to stock SMKY product in 2013. We have a compelling story to investors who know the food business and we've mitigated risk."

Smoky Market Foods, Inc. (SMKY), closed Thursday's trading session at $0.0385, up 25.82%, on 44,200 volume with 4 trades. The average volume for the last 60 days is 216,403 and the stock's 52-week low/high is $0.02/$0.248.


Today we are reporting on ENTREC Corp. (ENT.V), here at the QualityStocks Daily Newsletter.

ENTREC Corp. specializes in the lifting, transportation (over the road and on-site), loading, off-loading and setting of overweight and oversized cargo. The Company performs these for the oil and gas, construction, petrochemical, mining and power generation industries. They formally established their name ENTREC in 2008. However, ENTREC, via their founding company Schell Equipment, began operations as a specialized heavy hauler in 1995. ENTREC's common shares trade on the TSX Venture Exchange. ENTREC is based in Spruce Grove, Alberta.

The Company's business grew from a one truck and four trailer operation to a 35-employee business, before being acquired by Transco. Transco was purchased by Flint in 2006; the name was subsequently changed to ENTREC. They were purchased from Flint Energy by EIS Capital Corp. in May of 2011. The Company has established itself as a stand-alone company focusing on specialized transportation retaining the name ENTREC.

ENTREC has strategically placed operational hubs that provide services throughout western Canada and the Northwest Territories. They coordinate U.S. loads and operations from their Calgary location. ENTREC provides hauling of loads from major west coast American ports directly to their customer locations.

In early October, ENTREC announced that they signed an option to purchase a 10-acre property in Fort McMurray, Alberta. The option is exercisable at any time following the receipt of regulatory approval to the subdivision of the Property from the 27-acre parcel of land in which it is currently included. Once the Company receives regulatory approval to that subdivision, and the option is exercised, ENTREC intends to build a shop and office on the Property to support their Fort McMurray operations. This will allow the Company to significantly expand their Fort McMurray footprint and provide a base from which to grow substantially their on-site crane and heavy haul transportation services in the Fort McMurray region.

This week, ENTREC announced that they closed their previously announced offering of 7.00 percent convertible unsecured subordinated debentures. ENTREC issued and sold an aggregate $22,000,000 principal amount of Debentures at a price of $1,000 per Debenture. The Company's intention is to use the net proceeds of the Offering to fund future capital expenditures and, if necessary, for potential future business acquisitions, working capital and general corporate purposes.

ENTREC Corp. (ENT.V), closed Thursday's session at $1.57, even for the day, on 85,187 volume. The stock's 52-week low/high is $1.03/$1.75.

Northern Offshore Ltd. (NFSHF)

Today we are reporting on Northern Offshore Ltd. (NFSHF), here at the QualityStocks Daily Newsletter.

Founded in 2000, Northern Offshore Ltd. provides contract drilling equipment and operating services for offshore oil and gas companies. The Company's fleet consists of four drilling units - a drillship, a semisubmersible and two jackup drilling rigs - and one floating production facility. Northern Offshore's shares trade on the OTC Pink Current Information. A Bermuda holding company, Northern Offshore has their headquarters in Hamilton, Bermuda.

The Company operates in a variety of markets worldwide. This includes the North Sea, offshore Russia, the Mediterranean Sea, the Indian Ocean and Southeast Asia. In addition, Northern Offshore offers rig management services.  

Their Rig Fleet includes the Northern Producer, a semisubmersible floating production platform (FPF) of Aker H-3 design. It was originally built as a semisubmersible drilling rig in 1977 at the Trosvik Verft shipyard in Norway. The Northern Producer is able to handle oil production of 55,000 barrels per day, gas production of 60 million cubic feet per day, and water injection of 45,000 barrels per day.

The Company also has the Energy Searcher rig, a conventionally moored drill ship, able to operate in water depths of up to 2,500 ft. The rig was completely refurbished and upgraded in 2006 and underwent its five year SPS (May 2011) in Singapore, with additional upgrades in 2012. Currently, the Energy Searcher is operating offshore Vietnam. Another rig is the Energy Driller, a semisubmersible drilling rig of "Mariner" design. Constructed in 1977, it received subsequent upgrades in 1992, 1997, 2007 and 2012. It is able to operate in water depths of up to 1,000 ft and drilling depth of up to 20,000 ft. The rig is presently operating offshore India on a three-year contract with ONGC.

Additionally, Northern Offshore has their Energy Endeavour, one of the harsh environment jack ups rigs in the Northern Offshore Fleet. The design of the rig is for all year round operation in the southern North Sea and seasonally in the central North Sea. Currently it is operating in the Danish sector of the southern North Sea. Furthermore, the Company has the Energy Enhancer, another one of the harsh environment jack ups in the Northern Offshore fleet. The design of the rig is for all year round operation in the Southern North Sea and seasonally in the Central North Sea. It is currently preparing for a one-year contract with an operator in Denmark.

In mid-October, Northern Offshore announced that the pending sale of the jackup Energy Exerter to an undisclosed buyer was completed. They confirm the previous announcement on August 29, 2012 that the net proceeds from the sale after fees and expenses is approximately US$43.5 million, with a financial net gain of approximately US$7.5 million.

Northern Offshore Ltd. (NFSHF), closed Thursday's session at $1.76, even for the day, on 2,500 volume with 1 trade. The average volume for the last 60 days is 10,348 and the stock's 52-week low/high is $1.46/$3.00.

BonTerra Resources, Inc. (BTR.V)

The Ticker Tape Report reported yesterday on BonTerra Resources, Inc. (BTR.V), Vantage Wire, Stockhouse did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BonTerra Resources, Inc. is a Canadian gold exploration company based in Vancouver, British Columbia. They concentrate on continuing to expand the drill defined gold zones on their Eastern Extension property. This property is part of the world famous Abitibi Greenstone Belt in Quebec. BonTerra Resources' shares trade on the TSX Venture Exchange.

The Company has three gold properties in the Urban-Barry belt - the Eastern Extension, Lavoie and Urban-Barry properties. These are approximately 170 km NE of Val-d'Or and 125 km SW of Chibougamau in the Urban, Barry and Bailly townships in Quebec. BonTerra Resources owns 100 percent of the Eastern Extension property (from Abitex Resources) subject to a 2 percent Net Smelter Return (NSR).

BonTerra has completed a year-long 14,000 meter, 49 hole drill program. Significant historical drilling also took place on the property. Xemac Resources drilled a total of 8,650 meters in 59 diamond drill holes. All drilling on the property totals 22,570 meters in 108 diamond drill holes.

Since BonTerra Resources optioned the property from Abitex Resources in September of 2010, they have been very active in working the property. BonTerra has spent approximately $3,000,000 on a multi-faceted work program. This has included channel sampling, diamond drilling, ground magnetic survey, an IP survey as well as diamond drilling.

BonTerra Resources also has a British Columbia silver property called the Symphony property. The Symphony claims are contiguous to the Silver Queen Mine (silver-lead-zinc).

Yesterday, BonTerra Resources provided an update on their 100 percent owned Eastern Extension property. Recently, the Company completed a prospecting program that aimed to check IP anomalies (conductors) associates with magnetic highs along the NE-SW structures. They discovered two parallel structures identified on the magnetic map as well as the chargeability/resistivity map. BonTerra's geologist, Robert Gagnon and his team followed up and confirmed these structures.

Navjit Dhaliwal, BonTerra's President, stated, "The discovery of these parallel structures in our Peninsula and Rivage zone are exciting findings as we look to expand our drill targets for our upcoming drill program. BonTerra's technical team is currently preparing to carry out the drilling program on the Property beginning this fall which will be aimed at these new targets".

BonTerra Resources, Inc. (BTR.V), closed Thursday's trading session at $0.08, even for the day, on 394,000 volume. The stock's 52-week low/high is $0.06/$0.30.

ISC8, Inc. (ISCI)

We are reporting on ISC8, Inc. (ISCI) here at the QualityStocks Daily Newsletter.

Headquartered in Costa Mesa, California, ISC8, Inc. actively engages in the development and sale of intelligent cyber security solutions. These solutions are for information technology (IT) for commercial and government environments around the world. ISC8's Cyber products are targeted at detecting next-generation malware and Advanced Persistent Threats (APTs). Key industries the Company's team of security professionals assists include Energy, Financial Services, and Government/Public Sector. Key industries also include Healthcare, Retail/Internet Commerce, as well as Service Providers.

ISC8's sole focus is to deliver the most comprehensive cybersecurity solutions available. The design of their products is to solve the toughest challenges government, defense, and business face including the human or 8th layer. ISC8's concentration is on areas that provide IT security experts with actionable intelligent information required to make critical decisions and decisively respond to the threats that impact business.

The Company provides 3D stacked chip assemblies, high-speed processors, and miniaturized sensors – all technologies they have developed. ISC8 formerly went by the name Irvine Sensors Corp. They formally changed their name to ISC8, Inc. on January 24, 2012. Founded in 1974, the Company's shares trade on the OTCBB.

ISC8 has developed anti-tamper technology and sensors that extend beyond protecting information and traditional cyber security. The Company's sensors extend to focal plane arrays, readout integrated circuits, and 3-D stacked electronics. These sensors, upon combination with advanced cognitive processing techniques, deliver solutions to the broadest spectrum of possible emerging threats - including the human element.

ISC8's products include cyber security systems, such as processing boards, and related subsystems and electronic chassis; miniaturized infrared cameras; anti-tamper products that incorporate flash memories and processors; unattended aerial sensor systems; and stacked memory chips and stacked system assemblies. Their products have potential applications in cognitive systems, active imaging systems, 3-D systems, application specific electronic systems, and infrared sensors. In addition, the Company offers contract research and development services related to their products primarily for U.S. government customers or prime contractors.

In mid-October, ISC8 announced the completion of their acquisition of key assets of Bivio Networks, Inc. They announced on September 4, 2012 that they entered into an agreement to acquire certain cybersecurity related assets of Bivio Networks - a leading provider of cybersecurity solutions and products. The acquisition provides ISC8 with advanced products and technologies for Security Intelligence, Incident Response, Content Control and mitigation of Advanced Persistent Threats (APTs) in enterprise, service provider and government networks.

ISC8 purchased the NetFalcon and Network Content Control System business units of Bivio Networks. This includes all related intellectual property, sales, engineering, managerial, and other operational resources. ISC8 will also acquire an installed base consisting of nine accounts. These include leading Tier 1 service providers, enterprises and government agencies globally.

ISC8, Inc. (ISCI), closed Thursday's trading session at $0.091, even for the day. The average volume for the last 60 days is 84,697 and the stock's 52-week low/high is $0.07/$0.195.

LOGIC Devices, Inc. (LOGC)

SmallCap Fortunes reported earlier on LOGIC Devices, Inc. (LOGC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Sunnyvale, California, LOGIC Devices, Inc. develops and markets high-speed digital integrated circuits that perform high-density storage and signal/image processing functions. The Company's products are used in video broadcasting, medical imaging, military, industrial, embedded, and telecommunications markets. Founded in 1983, LOGIC Devices shares trade on the OTCQX U.S.

The Company's products enable video display, transport, editing, composition, and special effects. In addition, LOGIC provides solutions for digital filtering in base stations, image enhancement in medical diagnostic scanning and imaging equipment, and guidance and target recognition capabilities in smart-weapons systems. LOGIC focuses on developing high performance digital integrated circuits for applications requiring high-density embedded memory, high data rates and low power consumption.

LOGIC'S products address storage and digital signal processing (DSP) requirements that involve high-performance arithmetic computation. The Company concentrates on developing proprietary catalog products to address specific functional application needs or performance levels that are not otherwise commercially available. LOGIC works to provide related groups of circuits that original equipment manufacturers (OEMs) incorporate into high-performance electronic systems.

The Company provides solutions for digital filtering in television broadcast stations, and image enhancement in medical diagnostic scanning and imaging equipment. LOGIC Devices markets their products through a combination of direct sales, domestic sales representatives, and international distributors and/or agents. The Company's customers include Snell & Wilcox, Rohde & Schwarz, GE, Ziehm, Siemens, Hitachi, BAE, Ratheon, and Lockheed Martin.

LOGIC's solutions include Asychronous Static Random Access Memory (SRAM). They have a 1Mbit, 128K x 8 product grouping.  Their entire 1Mbit product members are available in multiple speeds, multiple hermetic package footprints and can be offered with either one or two chip enables. The Company's solutions also include Integrated Plastic Memory Modules (IMOD). Their IMODs provide high density, wide word memory arrays, sub-systems, and systems in a package.

LOGIC additionally offers a best-of-breed portfolio of Video and Image Processing products, and high performance programmable FIR Filter Engines. They also offer legacy DSP building blocks, including ALUs, Multipliers, DDS blocks, Coordinate Transformers, and Pipeline Registers.

LOGIC Devices, Inc. (LOGC), closed Thursday's session at $0.09, even for the day. The average volume for the last 60 days is 9,041 and the stock's 52-week low/high is $0.07/$0.51.

Talon Therapeutics, Inc. (TLON)

SmarTrend Newsletters, Real Pennies, and PennyTrader Publisher reported earlier on Talon Therapeutics, Inc. (TLON), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Founded in 2002, Talon Therapeutics, Inc. is a biopharmaceutical company headquartered in South San Francisco, California. The Company develops and commercializes new and differentiated cancer therapies. Their lead product candidate is Marqibo® (vinCRIStine sulfate LIPOSOME injection). Talon Therapeutics lists on the OTC Bulletin Board.

In addition to Marqibo®, the Company has additional pipeline opportunities. Some, like Marqibo®, have the potential to improve delivery, enhance the therapeutic benefits of well-characterized, proven chemotherapies, and enable high potency dosing without increased toxicity. Marqibo® is a new, targeted, nanoparticle-encapsulated, cancer therapeutic. The specific design of it is to improve patient outcomes by combining the potential for enhanced efficacy with the potential for reduced toxicity.

Marqibo® consists of vincristine sulfate, a potent vinca alkaloid anti mitotic, encapsulated in the aqueous core of proprietary, sphingomyelin-based liposomes called Optisomes™. This distinct formulation has undergone development to facilitate high-concentration, targeted drug delivery and predictable, first-order, continuous drug release kinetics.

Talon's product pipeline includes Menadione Topical Lotion. This is a topical compound for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitor anti-cancer treatment. Additionally, the Company has their Brakiva™ (topotecan liposomes injection, OPTISOME™) product. This is a novel, targeted, nanoparticle-encapsulated, anti-cancer compound for small cell lung and ovarian cancers. Moreover, Talon has their Alocrest™ (vinorelbine liposomes injection, OPTISOME™) product. This is a novel, targeted, nanoparticle-encapsulated, anti-cancer compound for lung and breast cancers.

Talon Therapeutics announced this past August that Marqibo® received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. This indication is based on overall response rate. Marqibo® has received orphan drug designation for the treatment of ALL from the FDA and from the European Medicines Agency (EMA). Talon Therapeutics intends to submit a Marketing Authorization Application to the EMA in 2013.

Talon Therapeutics, Inc. (TLON), closed Thursday's session at $0.57, up 7.14%, on 32,170 volume with 19 trades. The average volume for the last 60 days is 276,778 and the stock's 52-week low/high is $0.40/$1.83.

St. Andrew Goldfields Ltd. (SAS.TO)

We are highlighting St. Andrew Goldfields Ltd. (SAS.TO), here at the QualityStocks Daily Newsletter.

Based in Toronto, Ontario, St. Andrew Goldfields Ltd. (SAS) (operating as SAS Goldmines), is a gold mining and exploration enterprise. The Company has an extensive land package in the Timmins mining district, in northeastern Ontario, which lies within the Abitibi greenstone belt. At present, SAS operates the Holt, Holloway and Hislop Mines; the Company is targeting annual gold production of 90,000-100,000 ounces of gold for 2012. SAS lists on the Toronto Stock Exchange.

SAS is also advancing the Taylor Project and is conducting an aggressive exploration program across 120km of land straddling the Porcupine-Destor Fault Zone. They focused exploration at several sites and the Company has targeted the 2012 exploration program on areas that lie near to the existing mines and infrastructure. SAS is also focusing on following up on advanced exploration projects to add to the resource and reserve levels. In 2011, they increased their resource levels by 34 percent, and advanced the Taylor Project through the pre-feasibility stage.

In October, SAS reported record third quarter (Q3 2012) production of 25,742 ounces of gold from their Holt, Holloway and Hislop mines in the Timmins mining district. The Holt Mine produced 13,145 ounces of gold derived mainly from Zone 4 from the 925m Level and the 1075m Level mining areas, and a small contribution from the recently developed Zone 6. The head grade during the quarter was 5.40 g/t Au, 13 percent above the reserve grade of 5.18g/t Au. Mill recoveries were at their expected level of approximately 94 percent.

The Holloway Mine produced 5,408 ounces of gold from the Smoke Deep Zone. The mill recovery rate of 91 percent exceeded the Company's forecast because of improved mineralogical conditions in the areas mined during the quarter.  The Hislop Mine produced 7,187 ounces of gold in Q3 2012. The head grade averaged 2.53 g/t Au; this was substantially higher than the reserve grade of 1.88 g/t Au. Mill recovery for Hislop during the quarter averaged 86 percent. This is slightly below expectations because of the mining of zones with more mineralogical complexity that adversely affected the leach kinetics.

Last week, SAS announced their upcoming conference call to discuss their third quarter financial and operating results for 2012. The conference call will take place on Tuesday November 13, at 10:00 AM EST. The Company will release their third quarter financial results after market on Monday November 12, 2012.

St. Andrew Goldfields Ltd. (SAS.TO), closed Thursday's trading at $0.455, even for the day, on 91,123 volume. The stock's 52-week low/high is $0.31/$0.65.


The QualityStocks
Company Corner


TNI BioTech, Inc. (TNIB)

The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $4.84, up 7.56%, on 12,816 volume with 16 trades. The stock’s average daily volume over the past 60 days is 42,198, and its 52-week low/high is $0.72/$10.01.

TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.

The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.

The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer

TNI BioTech, Inc. Company Blog

TNI BioTech, Inc. News:

TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies

Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer

TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital

Skinny Nutritional Corp. (SKNY)

The QualityStocks Daily Newsletter would like to spotlight Skinny Nutritional Corp. (SKNY). Today, Skinny Nutritional Corp. closed trading at $0.002, even for the day, on 473,000 volume with 14 trades. The stock’s average daily volume over the past 60 days is 1,266,067, and its 52-week low/high is $0.0017/$0.035.

Skinny Nutritional Corp. (SKNY) has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water's proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water.

The company has constructed a network of approximately 50 domestic distributors (with three more internationally), placing product on shelves approximately 15k stores across the United States. Derived from the natural flavors contained in fruits, Skinny Water represents a fortified, extremely low-impact, great-tasting array of beverages that provide a concentrated punch of the nutrients essential for a healthier lifestyle.

The company's strong emphasis on health, fitness, and community has served marketing initiatives very well. The new age beverage segment has seen increasing momentum in recent years, with just about every beverage company getting into the game, but none of them has the kind of no-nonsense product composition behind Skinny Water, something that appeals directly to the majority of the core consumer market.

Skinny Nutritional continues to build value around the Skinny Water brand, and today has numerous trademarks in the healthy beverage and snack food categories. As consumers migrate away from sugar based beverages and empty calories, Skinny Water is ideally positioned to benefit from positive market trends as management focuses on delivering exceptional value to shareholders. Disclaimer

Skinny Nutritional Corp. Blog

Skinny Nutritional Corp. News:

Skinny Nutritional Corp. Provides Update on Discussions With Trim Capital

Skinny Nutritional Corp. to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+

A&P's 275 Stores Continue Skinny Water's Mid-Atlantic Penetration

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.25, even with yesterday's close, on 69,000 volume with 11 trades. The stock’s average daily volume over the past 60 days is 111,614, and its 52-week low/high is $0.21/$0.70.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corp's Lifeline Cell Technology Products to Be Added to Fisher Scientific's Catalogs

International Stem Cell Corp Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine

International Stem Cell Corp to Participate in Upcoming Investor Conference

Cardium Therapeutics, Inc. (CXM)

The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.1965, off by 4.15%, on 63,280 volume with 76 trades. The stock’s average daily volume over the past 60 days is 260,415, and its 52-week low/high is $0.1771/$0.47.

Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.

The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.

Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.

Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer

Cardium Therapeutics, Inc. Company Blog

Cardium Therapeutics, Inc. News:

FDA Considering Faster Approval Process for Developers of Drugs for Deadly or Debilitating Diseases

Cardium Announces the Acquisition of To Go Brands

Cardium To Present At 2012 Noble Financial Life Sciences Investor Conference

Lifeline Cell Technology Plays Important Role for International Stem Cell Corp. (ISCO)

Lifeline Cell Technology, a wholly owned subsidiary of International Stem Cell Corp., specializes in the research and production of purified human cells and optimized reagents for cell culture. Lifeline helped introduce Normal Human Cell Systems for research over 25 years ago, and developed many of the quality standards that academic, government, and pharmaceutical laboratories use today in the study of human diseases.

With laboratory and manufacturing operations in California and Maryland, Lifeline offers researchers a comprehensive range of human cell systems and associated products:

• Advanced Skin Test Products
• Bladder Cell Systems
• Corneal Epithelial Cell Systems
• Cryopreservation Solutions
• Endothelial Cell Systems
• Fibroblast Systems / Stem Cell Products
• Hematopoietic Systems
• Hepatocyte Products
• Keratinocyte Systems
• Special Edition Cells
• Melanocyte Cell Systems
• Prostate Cell Systems
• Pulmonary Cell Systems
• Renal Cell Systems
• RNA Products
• Smooth Muscle Cell Systems
• Stem Cell Systems, Human
• Stem Cell Systems, Non-Human
• Stain Kits
• Subculture Reagents
• Custom Products & Services

Lifeline products are sold around the world through international distributors serving Europe, Japan, Korea, China, India, Taiwan, and other countries. Most recently, the company announced that its cell technology products are now being added to Fisher Scientific’s online catalog as an Encompass Preferred Supplier. Fisher Scientific is the world’s largest such supplier to the life science industry, and large pharmaceutical companies typically purchase their R&D supplies using preferred supplier agreements. As such, the Fisher agreement represents an important new sales channel for Lifeline and an important development for ISCO.

For additional information, visit www.InternationalStemCell.com and www.LifelineCellTech.com

Cardium Therapeutics, Inc. (CXM) Sees Opportunity Outside The U.S.

When the FDA recently announced that it is considering a faster approval process for developers of drugs for serious diseases, it was important news for companies like Cardium Therapeutics, a San Diego-based health sciences and regenerative medicine developer. Development of a significant new drug is expensive and time consuming even without the regulatory requirements, and pressure has been mounting on the FDA to make the process more efficient. The goal of the new process is to allow quicker clinical trials, while also letting physicians administer the drugs to critical need patients where the benefits would outweigh the risks.

But pharmaceutical developers like Cardium are often not focused on the U.S. alone. Major markets can exist in other parts of the world where a given drug may fit special needs and conditions. In the case of Cardium, one of their lead products is Generx, a DNA-based angiogenic growth factor therapeutic designed to stimulate blood vessel growth around the heart. In places where costly and invasive surgical revascularization procedures, such as coronary artery bypass surgery and angioplasty/stents, may not be feasible, the kind of innovative and cost-effective treatment Generx represents is a good match.

It is expected that 80 percent of future increases in coronary heart disease will occur outside the United States, representing a significant opening for Cardium and Generx. Cardium CEO, Christopher Reinhard, recognizes the opportunity: “We believe that Generx may offer the potential for a one-time, non-surgical cost-efficient treatment option for patients with myocardial ischemia due to coronary artery disease.”

In June, Cardium announced that it had received clearance from the Russian Ministry of Health and Social Development to start the phase III registration study for Generx. The Russian Health Authority will brand Generx with the therapeutic drug trade name Cardionovo for purposes of marketing.

For additional information, visit www.CardiumTHX.com

HII Technologies, Inc. (HIIT) Launches Onsite Power Division for E&P Space with Heavy Capital Backup

HII Technologies, the power and water management innovation-focused, Houston-based oilfield services firm with a solid operational footprint in both Texas and Oklahoma, reported launching their new E&P operator-aligned, onsite portable power division today, South Texas Power (STP), in conjunction with issuance of a non-binding letter of intent that will bolster the launch via capital obtained through a strategic alliance with Power Reserve Corp.

This is a natural symbiosis of parallel architectures, with Power Reserve heavily deployed in the oilfield equipment space and STP geared towards hooking customers up with the latest and best in mission critical power hardware. STP is bound to make a killing in the localized power game for E&P’s, with so many companies today craving robust onsite power solutions, generally in operating areas where the power grid can’t reach or can’t handle the load required. The plan is to farm out a considerable inventory of generators and ancillary equipment, harnessing the customer-centric rental finesse accrued by industry veterans in both the TX and OK markets to deliver an oilfield services power platform supercharged by deep client engagement standards. HIIT intends to announce vital personnel additions in this area moving forward, and investors should be on the lookout in the near future for those reports as STP ramps up.

The oilfield services sector thrives on loyalty and proving that you can get the job done, deliver the goods, and not flinch when pressures inevitably mount. That is what makes the client-oriented approach STP will be taking so essential and HIIT management has gone to great lengths to ensure that top personnel will be employed for bridging the gap, bringing oilfield end markets that much closer to the innovation/commercialization technology window so vigorously advanced by the company since its inception. HIIT has really proven itself over the last five plus decades of aggressive, brilliant commercialization in water management solutions for E&P’s, providing high-cap, environmentally sound, 10-inch aluminum total mobile piping systems (complete with distribution manifolds, pumps, and road crossing). The experience HII Technologies has from working hand-in-hand with E&P operators to develop custom solutions will serve STP well as the company moves to secure additional power and water management territory.

The letter of intent with private firm, Power Reserve, will allow for a non-dilutive funding mechanism to accelerate the launch, bringing in some $3M in key hardware for STP’s rental inventory, with an initial $1.2M purchase of equipment already floated. The plan is to rent out to operators at a negotiated day rate and split the take on a shared basis between the two entities for the lifespan of the hardware obtained under the partnership. While the letter of intent is still subject to customary closing conditions, including the arrival at and execution of definitive agreements, the company is confident that alternative financing won’t be necessary.

CEO of HIIT, Matt Flemming, spoke immediately of the logistical shortfalls facing many operators when it comes to providing their infrastructure with power and boldly proclaimed that STP will be there to help operators solve the challenges presented by drilling in difficult locations. By making portable onsite power generation a no-brainer for E&P developers, who are already usually swamped with the technical and visceral complexities of running an extraction program, STP is going to be getting some real sweetheart provider relationships in the difficult, yet burgeoning domestic energy space. But then, when an outfit like STP can swoop in and solve all of your power problems with a robust array of rental hardware options, the technical know-how to execute, and the customer service attitude needed to make sure the solution fits the client’s dilemma precisely, it is hard not to fall in love and come back for more business.

President of Power Reserve Corp., Nancy P. Boyd, spoke of the huge synergy in this deal and called it a win-win scenario, with Power Reserve providing capital muscle for HIIT’s extremely deft handling of the oilfield equipment end of things. The best margins come from a provider that really knows what the operators need and STP will be fielding only the best, most in-demand solution sets, something which should please shareholders as the new division emerges to prominence.

For more information on HII Technologies www.HIIT Inc.com

Astex Pharmaceuticals, Inc. (ASTX) Forms Drug Discovery Alliance with CRT and Newcastle

Astex Pharmaceuticals announced yesterday it has signed a five-year strategic drug discovery alliance with Cancer Research Technology Limited (CRT) and Newcastle University.

As partners, the three entities will discover and develop new cancer drugs in collaboration with researchers at the Cancer Research UK Drug Discovery Program at the Northern Institute for Cancer Research (NICR, Newcastle University).

Astex will provide Newcastle University with GBP1 million annual funding during the five-year alliance, supporting research across biology, chemistry, pharmacology, and imaging at the NICR in order to identify and develop new cancer drugs and associated biomarkers, to develop tests and to determine which patients to treat and whether new drugs are working. Astex will retain an option to an exclusive global license for developing and commercializing pharmaceutical products from each alliance project. CRT and Newcastle will be eligible to receive development and regulatory milestone payments on exercise of the options, as well as on products that Astex takes into development; they are also eligible to receive royalties on product sales. The financial terms relating to the milestone payments and royalties have not been disclosed.

This broad strategic drug discovery alliance will provide Astex with world-leading translational research in oncology. The alliance will also build on a previous collaboration between Astex, Newcastle and CRT for FGFr, which is a key cancer target that led to the development of a clinical candidate that Astex’s partners at Janssen have recently taken into a Phase I clinical trial.

This significant collaboration will build on the successes and track records of all involved partners, further developing Cancer Research UK’s world-class cancer treatment research.

Astex Pharmaceuticals is a company focused on the discovery and development of novel small molecule therapeutics with an emphasis on oncology. Currently developing a proprietary pipeline of novel therapies, Astex is creating de-risked products for partnership with leading pharmaceutical companies. The company developed Dacogen and receives significant royalties from its worldwide sales.

For more information, visit www.astx.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors

The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251